Insurer Humana’s quarterly profit climbs 13 percent
Humana Inc. raised its 2011 earnings forecast, following the lead set by other big insurers, including competitor WellPoint Inc.
Health Care & Life Sciences
Articles
Ortho firms pull back on doc payments
The number of payments in excess of $1 million didn’t change substantially from year to year, but orthopedic companies sharply cut their fees to surgeons who received the smallest amounts.
Kaiser: Lack of competition endemic
In a new study, Indiana ranked as the 19th least-competitive state for individual health insurance and the 27th least-competitive for small-employer health insurance.
State’s first Alzheimer’s-only nursing home to open
American Senior Communities says Auguste's Cottage at Harrison Terrace on the east side of Indianapolis already has 90 residents.
Lilly wins European approval for new use of Alimta
Indianapolis-based drugmaker can now market lung cancer drug as a continuation maintenance therapy, potentially boosting sales after recent loss of patent on bestseller Zyprexa.
Zyprexa era comes to an end for Lilly
On Oct. 24, the U.S. Food and Drug Administration approved the first generic versions of Eli Lilly and Co.’s best-seller, ending 15 years of highly lucrative sales.
Startup aims to mend doctors’ social media woes
RepuChek software tracks, analyzes what’s being said about doctors on the Internet.
Lilly fights view that fate hinges on Alzheimer’s drug
Analysts have eyes on trial data for drug that could be a game-changer for the company.
Dow Agro improves quarterly revenue, profit
Indianapolis-based Dow AgroSciences on Thursday reported record third-quarter sales of $1.2 billion, up 27 percent from the same period a year ago.
Drug theft is ongoing battle for pharmacies
Over the last 12 months, the Indiana Board of Pharmacy has conducted license litigation involving at least 35 pharmacy personnel statewide who’ve been accused of stealing drugs from work.
WellPoint’s 3rd-quarter profit falls, but beats analyst estimates
WellPoint earned $683.2 million in the third quarter, down 7.6 percent from the same quarter a year ago. But the company boosted its per-share profit forecast for the rest of the year.
CNO Financial’s quarterly earnings, revenue rise
Carmel-based life and health insurer CNO Financial Group Inc. said Tuesday that its third-quarter earnings jumped nearly four times over last year's third-quarter results, but mostly because of a one-time tax-related gain.
FDA approves first generic versions of Zyprexa
Federal health officials on Monday approved the first generic versions of the blockbuster drug Zyprexa, which posted sales of $5.7 billion last year for Indianapolis-based drugmaker Eli Lilly and Co Inc.
Lilly: Vendors key after Zyprexa patent loss
Lilly’s patent-loss challenges—the biggest of which takes effect today—will force the company to rely even more on its 1,300 Indiana vendors.
WellPoint competitor Cigna buying HealthSpring
Cigna Corp. will buy fellow health insurer HealthSpring Inc. in a $3.8 billion deal as it becomes the latest managed care company to snap up a bigger share of the fast-growing Medicare Advantage market.
Insurance mandate lacks teeth, WellPoint CFO says
As constitutional challenges to the health reform law’s mandate to buy insurance advance, WellPoint Inc.’s chief financial officer reiterated that the company does not object to the mandate, just to its lack of penalties.
Hospitals scrambling to buy nursing homes
The hospitals owned by Boone and Hamilton counties are following the lead of Indianapolis-based Wishard Health Services and its parent organization by acquiring far-flung nursing homes, hoping the strategy proves as lucrative.
BioCrossroads seeds upstart medical device maker
BioCrossroads’ Indiana Seed Fund has invested $300,000 in a startup company chaired by a former Eli Lilly and Co. executive developing an absorbable stent.
Profit falls at Lilly but meets Wall Street expectations
The Indianapolis-based drugmaker earned $1.24 billion in the three months ended Sept. 30, down 5 percent from the same quarter a year ago, even as revenue surged 9 percent.
Lilly diabetes drug wins approval for expanded use
Eli Lilly and Co. and Amylin Pharmaceuticals Inc.’s Byetta has received expanded approval for use with the world’s top-selling insulin to treat Type 2 diabetes.